Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
101 hedge funds and large institutions have $269M invested in Adverum Biotechnologies in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 16 closing their positions.
1,032% more call options, than puts
Call options by funds: $2.68M | Put options by funds: $237K
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
40% more capital invested
Capital invested by funds: $192M → $269M (+$77.6M)
1% more funds holding
Funds holding: 100 → 101 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0.38% less ownership
Funds ownership: 5.89% → 5.51% (-0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WM
WS Management
Jacksonville,
Florida
|
+$6.46M |
| 2 |
BlackRock
New York
|
+$2.15M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$2.13M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
+$1.94M |
| 5 |
Primecap Management
Pasadena,
California
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$8.49M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.93M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.62M |
| 4 |
Alkeon Capital Management
New York
|
-$4.22M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.89M |
ADVM Hedge Fund Activity: Q3 2018 in Review
101 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2018, worth a combined $269M — up 40% from $192M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ADVM positions and 16 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.
The largest buyer was WS Management, opening a new position worth an estimated $6.46M. The largest seller was Highbridge Capital Management, cutting an estimated $8.49M.
- 101 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2018, up from 100 in Q2 2018.
- Funds reported $269M of Adverum Biotechnologies stock for Q3 2018, up 40% quarter-over-quarter.
- 17 funds opened new Adverum Biotechnologies positions in Q3 2018 and 16 closed out, a net change of +1 holder.
- The largest Adverum Biotechnologies buyer in Q3 2018 was WS Management, an estimated $6.46M added.
- The largest Adverum Biotechnologies seller in Q3 2018 was Highbridge Capital Management, an estimated $8.49M sold.
Based on aggregated 13F filings for Q3 2018.